FDA Panel Votes Against Approval of Noven Pharmaceuticals Inc.'s Menopause Drug
3/5/2013 8:00:41 AM
More...
|
FDA Accepts Noven Pharmaceuticals Inc.s NDA for an Investigational Nonhormonal Therapy for Menopausal Vasomotor Symptoms
11/13/2012 9:05:31 AM
More...
|
Noven Pharmaceuticals Inc.'s Nonhormonal Hot Flash Therapy Meets Phase III Goals
10/3/2012 6:40:55 AM
More...
|
Noven Pharmaceuticals Inc. (NOVN) Announces Commencement of Phase 2 Study of Investigational d-Amphetamine Transdermal System for ADHD
10/2/2012 10:18:14 AM
More...
|
Noven Pharmaceuticals Inc. (NOVN) Submits New Drug Application for Investigational Non-Hormonal Therapy for Menopausal Vasomotor Symptoms
8/29/2012 9:43:33 AM
More...
|
Noven Pharmaceuticals Inc. (NOVN) Provides Update on Lidoderm® Patent Challenge
7/2/2012 11:11:22 AM
More...
|
Noven Pharmaceuticals Inc. (NOVN) Completes Phase 3 Clinical Program for Investigational Non-Hormonal Therapy for Menopausal Vasomotor Symptoms
3/21/2012 6:03:13 AM
More...
|
Noven Pharmaceuticals Inc. (NOVN) Announces Phase 3 Results for Investigational Non-Hormonal Therapy for Vasomotor Symptoms
12/28/2011 6:10:35 AM
More...
|
Noven Pharmaceuticals Inc. (NOVN) Completes Acquisition of Daytrana(R) Methylphenidate Transdermal System (CII) from Shire plc
10/1/2010 11:12:47 AM
More...
|
Shire plc Sells ADHD Patch Daytrana to Noven Pharmaceuticals Inc. (NOVN)
8/11/2010 6:58:09 AM
More...
|
|